Atovaquone is a Oral Suspension in the Human Prescription Drug category. It is labeled and distributed by Lohxa. The primary component is Atovaquone.
Product ID | 70166-488_9a19deb0-f27c-b93d-e053-2a95a90aa48b |
NDC | 70166-488 |
Product Type | Human Prescription Drug |
Proprietary Name | Atovaquone |
Generic Name | Atovaquone |
Dosage Form | Suspension |
Route of Administration | ORAL |
Marketing Start Date | 2018-10-11 |
Marketing Category | ANDA / ANDA |
Application Number | ANDA210692 |
Labeler Name | Lohxa |
Substance Name | ATOVAQUONE |
Active Ingredient Strength | 750 mg/5mL |
Pharm Classes | Antimalarial [EPC],Antiprotozoal [EPC] |
NDC Exclude Flag | N |
Listing Certified Through | 2020-12-31 |
Marketing Start Date | 2018-12-03 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | ANDA |
Application Number | ANDA210692 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2018-12-03 |
Marketing Category | ANDA |
Application Number | ANDA210692 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2018-12-03 |
Ingredient | Strength |
---|---|
ATOVAQUONE | 750 mg/5mL |
SPL SET ID: | ba3cad0d-cce9-424f-ba5c-557dba8bef12 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI | |
UPC Code |
NDC | Brand Name | Generic Name |
---|---|---|
0121-0888 | Atovaquone | Atovaquone |
0121-0898 | Atovaquone | Atovaquone |
0121-1796 | Atovaquone | Atovaquone |
0904-7064 | Atovaquone | Atovaquone |
16714-900 | atovaquone | atovaquone |
31722-629 | Atovaquone | Atovaquone |
50268-086 | Atovaquone | Atovaquone |
51407-642 | Atovaquone | Atovaquone |
60687-534 | Atovaquone | Atovaquone |
65162-693 | ATOVAQUONE | ATOVAQUONE |
66689-062 | Atovaquone | Atovaquone |
66993-062 | Atovaquone | atovaquone |
68180-282 | Atovaquone | Atovaquone |
68462-421 | atovaquone | atovaquone |
70166-488 | Atovaquone | Atovaquone |
10702-223 | Atovaquone Oral Suspension | Atovaquone |
0173-0547 | MEPRON | atovaquone |
0173-0665 | MEPRON | atovaquone |